Tresiba and Finasteride Interaction: Safety, Risks, and Clinical Guidance

The direct answer

Tresiba (insulin degludec) and finasteride use separate metabolic and elimination pathways. Insulin degludec is degraded like endogenous insulin by nonspecific peptidases and does not pass through cytochrome P450 enzymes; finasteride is cleared hepatically through CYP3A4. This separation is the reason neither drug's FDA-approved label lists the other as an interacting agent. What remains genuinely uncertain is a pharmacodynamic question: finasteride lowers dihydrotestosterone (DHT) and modestly raises testosterone, and androgens have documented links to insulin sensitivity in other contexts (such as androgen deprivation therapy for prostate cancer). Whether that shift produces a clinically detectable glucose effect in an individual patient on basal insulin has not been established by controlled evidence, so a cautious but not alarmed monitoring approach is the reasonable default.

Why this combination comes up often

Men who use Tresiba for type 2 diabetes are also a population at meaningfully elevated risk for androgenetic alopecia and benign prostatic hyperplasia, the two conditions finasteride treats. Type 2 diabetes is common in the United States; the Centers for Disease Control and Prevention's national diabetes surveillance data documents tens of millions of adults living with diabetes (CDC National Diabetes Statistics Report, most recent update reviewed 2026) [1]. Because both conditions increase with age and both drugs are common in mid-life and older men, the same patient asking about hair loss or urinary symptoms while on basal insulin is not an unusual clinical scenario.

Is there a pharmacokinetic interaction?

No pharmacokinetic interaction has been identified, and the mechanistic reason is straightforward.

Insulin degludec is a peptide hormone. Like native human insulin, it is broken down by peptidases in the liver, kidney, and peripheral tissue rather than by cytochrome P450 enzymes. The FDA-approved prescribing information for Tresiba does not list finasteride, or any CYP3A4 substrate, as an interacting drug [2]. Peptide insulins in general are not expected to participate in CYP-mediated interactions because they are not metabolized through that system.

Finasteride is a small molecule cleared primarily by CYP3A4. Its FDA label states that formal drug-interaction studies have not identified clinically important interactions [3]. Because insulin degludec never enters the CYP pathway, and finasteride does not inhibit or induce CYP enzymes at therapeutic doses, there is no shared enzymatic route through which one drug could raise or lower the blood level of the other.

Protein binding is a secondary theoretical concern. Finasteride is highly bound to plasma proteins, and insulin degludec's multi-hexamer complex also binds albumin, which is part of what extends its duration of action. Binding at different molecular sites, at the low concentrations typical of both drugs' therapeutic doses, has not produced a reported displacement interaction in clinical use.

The unresolved pharmacodynamic question: androgens and insulin sensitivity

Finasteride inhibits type II 5-alpha reductase, which converts testosterone to DHT. This lowers serum DHT and modestly raises circulating testosterone. Androgen status is known to influence glucose metabolism in some settings; for example, androgen deprivation therapy in men with prostate cancer, which lowers testosterone substantially, has been associated with worsened insulin resistance in published research. Finasteride is pharmacologically distinct from androgen deprivation therapy: it shifts the testosterone-to-DHT ratio rather than lowering overall androgen exposure, and total testosterone tends to rise slightly rather than fall.

Whether this ratio shift produces a clinically meaningful effect on insulin sensitivity or glycemic control has not been established in controlled, insulin-treated populations. Observational data on finasteride users have generally not shown a strong population-level signal for new-onset diabetes, but the specific studies referenced in earlier drafts of this topic could not be verified against the primary literature for this rewrite, and their exact effect sizes should not be treated as confirmed until checked against the original publications. The honest position is: a population-level glycemic effect from finasteride has not been demonstrated, an individual, idiosyncratic effect in a specific patient cannot be ruled out, and glucose monitoring after starting finasteride is a reasonable precaution rather than confirmation of a known risk.

What the FDA labels do and do not say

Both labels are reviewed and update periodically; specifics below reflect the versions accessible at the time of this review (2026) and should be re-checked at accessdata.fda.gov before relying on exact wording.

• The Tresiba label describes insulin degludec's peptide degradation pathway and lists drug classes known to affect glucose control (sulfonylureas, other antidiabetic agents, corticosteroids, thiazides, beta-blockers, and others), but does not list finasteride [2].
• The finasteride label describes CYP3A4 metabolism and reports that formal interaction studies have not identified clinically important interactions with other drugs tested [3].
• Neither label contains a warning, contraindication, or dose-adjustment recommendation for co-administration of these two specific drugs.

Absence of a listed interaction is not the same as a completed dedicated interaction study between these two specific drugs; it reflects that no signal has been strong enough, or the combination common enough in trial populations, to generate a labeled warning.

Drugs that do interact with Tresiba

Clinicians should keep attention on medications with an actual documented effect on insulin's glucose-lowering action, since finasteride is not one of them. According to the Tresiba label, drugs that can increase hypoglycemia risk when combined with insulin include other antidiabetic agents (sulfonylureas, GLP-1 receptor agonists, SGLT2 inhibitors), ACE inhibitors and ARBs, monoamine oxidase inhibitors, salicylates, fluoxetine, and pramlintide [2]. Drugs that may reduce insulin's glucose-lowering effect include corticosteroids, thiazide diuretics, thyroid hormone replacement, sympathomimetics, and some atypical antipsychotics [2]. Beta-blockers and alcohol can affect glucose in either direction and can mask hypoglycemia symptoms. Finasteride is not listed in either category.

A practical monitoring approach for patients on both drugs

Adding any new medication to an insulin regimen is a reasonable trigger for closer self-monitoring, independent of whether a specific interaction is documented. A general approach:

• Baseline fasting glucose (and HbA1c, if due) before starting finasteride
• More frequent fasting glucose checks during the first few weeks after starting finasteride
• A follow-up HbA1c at the next routine interval to confirm no meaningful drift
• Awareness that fatigue, mood changes, or low energy, which finasteride can cause in a minority of users, may be confused with hypoglycemia or hyperglycemia symptoms; a glucose check, not symptom guesswork, should confirm suspected hypoglycemia
• Communication between the prescriber managing finasteride (often dermatology or urology) and the prescriber managing insulin, so both are aware of the full medication list

Evidence-status interaction assessment

Evidence boundary

Established: insulin degludec and finasteride are metabolized through unrelated pathways, and neither FDA label documents a drug interaction between them. Plausible but unproven: finasteride's hormonal effects could, in principle, nudge insulin sensitivity in some patients, based on general androgen-glucose physiology rather than finasteride-specific insulin-cohort data. Not established: that this theoretical effect translates into a measurable, population-level change in glycemic control for patients on basal insulin. Readers and clinicians should treat any specific effect-size claim about finasteride and diabetes risk as unverified until checked against a primary study, since the studies previously cited for this topic could not be confirmed during this review.

When to contact a prescriber

Contact the prescriber managing insulin therapy if fasting glucose values run consistently and meaningfully above the pre-finasteride baseline for more than a few days, if continuous glucose monitoring shows a sustained drop in time-in-range after starting finasteride, or if new or worsening hypoglycemia symptoms appear. These are general insulin-safety triggers, not findings specific to the finasteride combination, and they warrant a glucose check rather than assumption before adjusting any dose. Any dose change to Tresiba should be made only in consultation with the prescribing clinician; this article does not provide individualized dosing guidance.